SRI receives two contracts from NHLBI
SRI researchers will support NHLBI’s Science Moving TowArds Research Translation and Therapy (SMARTT) Program to provide resources that assist translation to the clinic of novel therapeutics for the
Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta (quizartinib), an oral type II FLT3 inhibitor, in China.
Calcitonin is a drug indicated for the treatment of postmenopausal osteoporosis, hypercalcemia, and Paget’s disease, and is commercially available in subcutaneous, intramuscular and nasal routes. The open-label, single-dose,